Product name: Tamoxifen
Trade names: Nolvadex, Istubal, Valodex, Genox
CAS Registry Number: 10540-29-1
Einecs No: 234-118-0
Character: White crystalline powder.
Usage: For the treatment of advanced, recurrent breast cancer and ovarian cancer and other illnesses. Used as an antineoplastic raw materials.
Other drugs in same class:Anastrozole,Letrozole,Tamoxifen citrate,Exemestane
Nolvadex (tamoxifen citrate) is very comparable to Clomid, behaves in the same manner in all tissues, and is a mixed estrogen agonist/antagonist of the same type as Clomid. The two molecules are also very similar in structure. It is not correct that Nolvadex reduces levels of estrogen: rather, it blocks estrogen from estrogen receptors and, in those tissues where it is an antagonist, causes the receptor to do nothing. The belief that it reduces gains seems to stem from the fact that the scientific literature reports a slight reduction in IGF-1 (individuals using anabolic steroids were not studied though) from use of Nolvadex.
Thus, Dan Duchaine reported that it reduces IGF-1 and therefore reduces gains. However, if this effect exists at all, it must be very minor, due to the excellent gains that many have made, and from the fact that no one has noticed any such thing from Clomid, which has the same activity profile. The fact that Nolvadex will reduce water retention may result in the user agreeing that gains are less, since weight gain is less, thus reinforcing the bias.,
Tamoxifen is an antagonist of the estrogen receptor in breast tissue via its active metabolite, 4-hydroxytamoxifen. In other tissues such as the endometrium, it behaves as an agonist, and thus may be characterized as a Selective estrogen-receptor modulator. Tamoxifen is the usual endocrine (anti-estrogen) therapy for hormone receptor-positive breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting.
Tamoxifen is used to treat infertility in women with anovulatory disorders. A dose of 10-40 mg per day is administered in days 3-7 of a womans cycle.In addition, a rare condition occasionally treated with tamoxifen is retroperitoneal fibrosis. Tamoxifen is currently used for the treatment of both early and advanced ER+ (estrogen receptor positive) breast cancer in pre- and post-menopausal women. Additionally, it is the most common hormone treatment for male breast cancer.It is also approved by the FDA for the prevention of breast cancer in women at high risk of developing the disease.It has been further approved for the reduction of contralateral (in the opposite breast) cancer.
Tamoxifen also increase the risk of adverse side effects. Some cases of lower-limb lymphedema have been associated with the use of tamoxifen, due to the blood clots and deep vein thrombosis (DVT) that can be caused by this medication. Resolution of the blood clots or DVT is needed before lymphedema treatment can be initiated.
|Product name||Tamoxifen (Nolvadex)|
|Appearance||White crystalline powder|
|Identification||IR , UV conform||Conform|
|Loss on drying||≤0.5ml||0.21ml|
|Residue on ignition||Not more than 0.2%||0.07ml|
|Iron||Not more than 0.005%||0.0017%|
|Heavy metals||Not more than 0.001%||0.0006%|
|Related substances||Total: Not more than 1.0%|
Individual: Not more than 0.5%
|E-isomer||Not more than 0.3%||0.18%|
|Organic volatile impurities||Conforms||Conforms|
Tamoxifen Nolvadex Powder CAS 10540-29-1 For Body Images